Literature DB >> 20946107

Was the C282Y mutation an Irish Gaelic mutation that the Vikings helped disseminate? HLA haplotype observations of hemochromatosis from the west coast of Sweden.

Karl Sigvard Olsson1, Jan Konar, Inge Hoegh Dufva, Anne Ricksten, Ruma Raha-Chowdhury.   

Abstract

UNLABELLED: The HLA-related hemochromatosis mutation C282Y is thought to have originated in Ireland in a person with HLA-A3-B14 and was spread by Vikings. Irish people with two HLA-A3 alleles had a high risk of hemochromatosis. In this study, from west Sweden, we wanted to test these hypotheses.
METHODS: HFE mutations in controls, bone marrow donors with HLA-A3/A3 and patients with hemochromatosis. HLA haplotypes, extended haplotype analysis and pedigree studies.
RESULTS: The allelic C282Y frequency 0.04, (CI 0.01-0.07) was lower (P < 0.001) in Sweden than in Ireland 0.10 (CI 0.08-0.11), and Swedish bone marrow donors with HLA-A3/A3 (n = 77) had a low risk of hemochromatosis. HLA haplotypes available from 239/262 (91.5%) proband patients homozygous for C282Y showed a dominance of A3-B7 and A3-B14 both in linkage disequilibrium with controls (P < 0.001). Pedigree studies extended into the 17th century supported a local founder effect of A3-B14 in the county of Bohuslän. The A3-B14 haplotype may well be the original and A3-B7 the result of centromeric recombinations. The haplotype diversity and recombination events were not different from a Celtic series. These findings do not support the hypothesis of the C282Y mutation being of an Irish Celtic origin.
CONCLUSIONS: The C282Y frequency shows a west to east decline from Ireland through the north of Europe. Vikings may have been involved in the spread of C282Y, but the mutation is probably older and may have been spread in Europe by earlier seafarers.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946107     DOI: 10.1111/j.1600-0609.2010.01536.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Intragenic haplotype analysis of common HFE mutations in the Portuguese population.

Authors:  Sandra Toste; Luís Relvas; Catarina Pinto; Celeste Bento; Augusto Abade; M Letícia Ribeiro; Licínio Manco
Journal:  J Genet       Date:  2015-06       Impact factor: 1.166

2.  Hemorrhagic colitis induced by trientine in a 51-year-old patient with Wilson's disease waiting for liver transplantation: A case report.

Authors:  Andreas Schult; Matts Andersson; Jorge Asin-Cayuela; Karl Sigvard Olsson
Journal:  World J Hepatol       Date:  2022-08-27

3.  Effects of highly conserved major histocompatibility complex (MHC) extended haplotypes on iron and low CD8+ T lymphocyte phenotypes in HFE C282Y homozygous hemochromatosis patients from three geographically distant areas.

Authors:  Mónica Costa; Eugénia Cruz; James C Barton; Ketil Thorstensen; Sandra Morais; Berta M da Silva; Jorge P Pinto; Cristina P Vieira; Jorge Vieira; Ronald T Acton; Graça Porto
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

4.  The evolutionary adaptation of the C282Y mutation to culture and climate during the European Neolithic.

Authors:  Kathleen M Heath; Jacob H Axton; John M McCullough; Nathan Harris
Journal:  Am J Phys Anthropol       Date:  2016-01-22       Impact factor: 2.868

5.  Common founder effects of hereditary hemochromatosis, Wilson´s disease, the long QT syndrome and autosomal recessive deafness caused by two novel mutations in the WHRN and TMC1 genes.

Authors:  K Sigvard Olsson; Olof Wålinder; Ulf Jansson; Maria Wilbe; Marie-Louise Bondeson; Eva-Lena Stattin; Ruma Raha-Chowdhury; Roger Williams
Journal:  Hereditas       Date:  2017-12-19       Impact factor: 3.271

6.  Contributions of HFE polymorphisms to brain and blood iron load, and their links to cognitive and motor function in healthy adults.

Authors:  Grégoria Kalpouzos; Francesca Mangialasche; Farshad Falahati; Erika J Laukka; Goran Papenberg
Journal:  Neuropsychopharmacol Rep       Date:  2021-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.